Regentis Biomaterials Advances GelrinC Hydrogel for Knee Cartilage Repair

Regentis Biomaterials Ltd. (NYSE American: RGNT) is making significant strides in orthopedic medicine with its innovative GelrinC(R) hydrogel implant, designed to repair knee cartilage damage through a single, minimally invasive procedure lasting approximately 10 minutes. This cell-free, off-the-shelf solution addresses a critical unmet need: roughly 472,500 arthroscopic knee procedures in the U.S. each year involve cartilage damage, yet no approved regenerative product capable of restoring hyaline-like cartilage exists in the U.S. market. Unlike traditional microfracture or complex cell-based therapies that often require multiple surgeries and lengthy preparation, GelrinC(R) is a ready-to-use implant that supports native cartilage regeneration over time. The product has already received CE Mark approval in Europe and is advancing through a pivotal U.S. FDA trial now more than 50% enrolled. Regentis is also preparing for commercialization, highlighted by a newly patented solvent-free manufacturing process that increased production yield by 400%, alongside ongoing efforts to build physician adoption infrastructure across Europe.

To view the full article, visit https://ibn.fm/TrCv1. The company's latest news and updates relating to RGNT are available in its newsroom at https://ibn.fm/RGNT. Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis’ Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. GelrinC(R) aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.

This news was disseminated by BioMedWire, a specialized communications platform focusing on the Biotechnology, Biomedical Sciences, and Life Sciences sectors. BioMedWire is part of the Dynamic Brand Portfolio @ IBN that delivers a vast network of wire solutions, editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of followers, and a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BioMedWire is uniquely positioned to serve private and public companies seeking to reach a wide audience of investors, influencers, consumers, journalists, and the general public.